uniQure N.V. Files 8-K Report
Ticker: QURE · Form: 8-K · Filed: Oct 15, 2024 · CIK: 1590560
| Field | Detail |
|---|---|
| Company | Uniqure N.V. (QURE) |
| Form Type | 8-K |
| Filed Date | Oct 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, disclosure
TL;DR
uniQure filed an 8-K, likely routine disclosures. Watch for details.
AI Summary
On October 15, 2024, uniQure N.V. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates uniQure is providing updates or disclosures to the SEC, which could contain important information for investors regarding the company's financial status or regulatory compliance.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a change in risk.
Key Players & Entities
- uniQure N.V. (company) — Registrant
- October 15, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing by uniQure N.V.?
The filing is primarily for Regulation FD disclosures and to report financial statements and exhibits.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is October 15, 2024.
What is the principal executive office address for uniQure N.V.?
The address is Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands.
What is uniQure N.V.'s telephone number?
The company's telephone number is +31 - 20-566-7394.
Under which section of the Securities Exchange Act is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 555 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-10-15 07:49:04
Filing Documents
- qure-20241015x8k.htm (8-K) — 34KB
- qure-20241015xex99d1.htm (EX-99.1) — 17KB
- qure-20241015xex99d1001.jpg (GRAPHIC) — 8KB
- 0001558370-24-013276.txt ( ) — 181KB
- qure-20241015.xsd (EX-101.SCH) — 3KB
- qure-20241015_lab.xml (EX-101.LAB) — 15KB
- qure-20241015_pre.xml (EX-101.PRE) — 10KB
- qure-20241015x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 15, 2024, uniQure N.V. (the " Company ") issued a press release announcing the dosing of the first patient in the Company's Phase I/II clinical trial of AMT-162 for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in superoxide dismutase 1 (SOD1). A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liability of such section, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended (the " Securities Act "), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of uniQure N.V. dated October 15, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. UNIQURE N.V. Date: October 15, 2024 By: /s/ Jeannette Potts JEANNETTE POTTS Chief Legal and Compliance Officer